<DOC>
	<DOCNO>NCT00690066</DOCNO>
	<brief_summary>The purpose study establish safety efficacy multiple administration PROCHYMAL® subject recently diagnose type 1 diabetes mellitus .</brief_summary>
	<brief_title>PROCHYMAL® ( Human Adult Stem Cells ) Treatment Recently Diagnosed Type 1 Diabetes Mellitus ( T1DM )</brief_title>
	<detailed_description>Diabetes mellitus refers disorder body trouble control blood glucose level . There two main type diabetes : type 1 type 2 . Type 1 diabetes mellitus ( T1DM ) , study trial , autoimmune disorder body 's immune system attack destroy cell make insulin . These cell call beta cell . As beta cell destroy , less insulin make . This cause blood sugar level increase normal cause life-threatening hypo- hyper-glycemic reaction . For reason , people type 1 diabetes must take insulin help control blood sugar level . Over time , poorly control diabetes lead variety serious health condition , include heart disease , stroke , blindness , amputation , kidney disease , nerve damage . Insulin primary method control diabetes regulate blood glucose level , may reverse prevent disease progression . The active ingredient ROCHYMAL® adult human mesenchymal stem cell ( MSCs ) . MSCs show interact immune cell body , reduce inflammation assist tissue repair . This study help determine whether MSCs protect normal pancreatic tissue autoimmune attack repair damage pancreatic tissue , lead increase insulin production decrease circulate blood glucose . The characteristic biologic activity PROCHYMAL® , along good safety profile human trial date , suggest PROCHYMAL® may good candidate address Type 1 Diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Subject must diagnosis type 1 diabetes mellitus base ADA criterion Subject must screen 2 20 week initial T1DM diagnosis Subject must age 12 35 ( inclusive ) Subject must least one diabetesrelated autoantibody present ( either GAD IA2 ) Subject must beta cell function determine Cpeptide test Subject must willing comply `` intensive diabetes management '' direct Investigator goal maintain blood glucose close normal possible Subject must willing comply schedule study visit protocol requirement Subject Body Mass Index ( BMI ) ≥ 30 Subject evidence retinopathy baseline Subject abnormally high lipid level Subject abnormal blood pressure Subject abnormal serum creatinine Subject evidence clinically significant proteinuria Subject diabetic ketoacidosis Subject treat severe active infection type A female subject breastfeeding , pregnant , intend become pregnant study Subject clinically relevant uncontrolled medical condition associate diabetes ( e.g . hematologic , renal , hepatic , neurologic , cardiac , respiratory ) Subject allergic bovine porcine product Subject evidence active malignancy , prior history active malignancy remission least 5 year</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>T1DM</keyword>
	<keyword>Type 1 Diabetes Mellitus</keyword>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Diabetes Mellitus , Insulin-Dependent</keyword>
	<keyword>Juvenile Diabetes</keyword>
	<keyword>Adult Human Stem Cells</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>MSCs</keyword>
	<keyword>Insulin</keyword>
	<keyword>Osiris</keyword>
	<keyword>Prochymal</keyword>
</DOC>